STOCK TITAN

[Form 4] KALA BIO, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

KALA BIO (KALA) disclosed an insider transaction by a director. On 10/23/2025, the reporting person sold 154,894 shares of common stock at a $0.81 weighted average price, with individual trades executed between $0.78 and $0.85. Following the sale, the reporting person beneficially owns 103,540 shares, reported as unvested RSUs, held directly.

The filing notes the price is a weighted average and that detailed trade breakdowns within the stated range are available upon request.

KALA BIO (KALA) ha divulgato una operazione interna da parte di un dirigente. Il 10/23/2025, la persona che segnala ha venduto 154.894 azioni ordinarie a un prezzo medio ponderato di $0.81, con operazioni individuali eseguite tra $0.78 e $0.85. Dopo la vendita, la persona che segnala detiene beneficiamente 103.540 azioni, riportate come RSU non vestite, detenute direttamente.

La dichiarazione indica che il prezzo è una media ponderata e che dettagliate suddivisioni delle operazioni entro l'intervallo indicato sono disponibili su richiesta.

KALA BIO (KALA) reveló una operación interna por parte de un director. El 23/10/2025, la persona que reporta vendió 154,894 acciones de acciones comunes a un precio medio ponderado de $0.81, con operaciones individuales ejecutadas entre $0.78 y $0.85. Después de la venta, la persona que reporta posee beneficiosamente 103,540 acciones, reportadas como RSU no vestidas, mantenidas directamente.

El archivo indica que el precio es una media ponderada y que desgloses detallados de las operaciones dentro del rango indicado están disponibles a petición.

KALA BIO (KALA) 이사는 내부자 거래를 공개했다. 2025/10/23에 보고자는 154,894주의 보통주를 가중평균가 $0.81로 매도했으며, 개별 거래는 $0.78에서 $0.85 사이에서 체결되었다. 매도 후 보고자는 103,540주의 주식을 직접 보유하며 RSU로 아직 vest되지 않은 상태로 보고된다.

신고서에는 가격이 가중평균이며, 명시된 구간 내의 상세 거래 내역이 요청 시 제공될 수 있다고 명시되어 있다.

KALA BIO (KALA) a divulgué une opération interne par un administrateur. Le 23/10/2025, la personne déclarante a vendu 154 894 actions ordinaires à un prix moyen pondéré de $0,81, avec des transactions individuelles exécutées entre $0,78 et $0,85. Suite à la vente, la personne déclarante détient avantageusement 103 540 actions, déclarées comme des RSU non acquises, détenues directement.

Le dépôt indique que le prix est une moyenne pondérée et que des détails de répartition des transactions dans l'intervalle indiqué sont disponibles sur demande.

KALA BIO (KALA) gab eine Insider-Transaktion durch einen Direktor bekannt. Am 23.10.2025 verkaufte die meldende Person 154.894 Aktien Stammaktien zu einem gewichteten durchschnittlichen Preis von $0.81, wobei einzelne Trades zwischen $0.78 und $0.85 ausgeführt wurden. Nach dem Verkauf besitzt die meldende Person vorteilhaft 103.540 Aktien, berichtet als unvested RSUs, direkt gehalten.

Die Einreichung weist darauf hin, dass der Preis ein gewichteter Durchschnitt ist und dass detaillierte Handelsaufschlüsselungen innerhalb des angegebenen Bereichs auf Anfrage verfügbar sind.

KALA BIO (KALA) كشفت عن عملية داخلية من قبل مدير. في 23/10/2025، باعت الشخص المُبلغ عنه 154,894 سهماً من الأسهم العادية بسعر متوسط مرجح قدره $0.81، مع تنفيذ صفقات فردية بين $0.78 و $0.85. بعد البيع، يملك الشخص المُبلغ عنه بنحو مفاد 103,540 سهماً، مُسجلة كـ RSUs غير vesting ومملوكة بشكل مباشر.

تشير الوثيقة إلى أن السعر هو سعر متوسط مرجح وأن تفصيلات التداول داخل النطاق المحدد متاحة عند الطلب.

Positive
  • None.
Negative
  • None.

KALA BIO (KALA) ha divulgato una operazione interna da parte di un dirigente. Il 10/23/2025, la persona che segnala ha venduto 154.894 azioni ordinarie a un prezzo medio ponderato di $0.81, con operazioni individuali eseguite tra $0.78 e $0.85. Dopo la vendita, la persona che segnala detiene beneficiamente 103.540 azioni, riportate come RSU non vestite, detenute direttamente.

La dichiarazione indica che il prezzo è una media ponderata e che dettagliate suddivisioni delle operazioni entro l'intervallo indicato sono disponibili su richiesta.

KALA BIO (KALA) reveló una operación interna por parte de un director. El 23/10/2025, la persona que reporta vendió 154,894 acciones de acciones comunes a un precio medio ponderado de $0.81, con operaciones individuales ejecutadas entre $0.78 y $0.85. Después de la venta, la persona que reporta posee beneficiosamente 103,540 acciones, reportadas como RSU no vestidas, mantenidas directamente.

El archivo indica que el precio es una media ponderada y que desgloses detallados de las operaciones dentro del rango indicado están disponibles a petición.

KALA BIO (KALA) 이사는 내부자 거래를 공개했다. 2025/10/23에 보고자는 154,894주의 보통주를 가중평균가 $0.81로 매도했으며, 개별 거래는 $0.78에서 $0.85 사이에서 체결되었다. 매도 후 보고자는 103,540주의 주식을 직접 보유하며 RSU로 아직 vest되지 않은 상태로 보고된다.

신고서에는 가격이 가중평균이며, 명시된 구간 내의 상세 거래 내역이 요청 시 제공될 수 있다고 명시되어 있다.

KALA BIO (KALA) a divulgué une opération interne par un administrateur. Le 23/10/2025, la personne déclarante a vendu 154 894 actions ordinaires à un prix moyen pondéré de $0,81, avec des transactions individuelles exécutées entre $0,78 et $0,85. Suite à la vente, la personne déclarante détient avantageusement 103 540 actions, déclarées comme des RSU non acquises, détenues directement.

Le dépôt indique que le prix est une moyenne pondérée et que des détails de répartition des transactions dans l'intervalle indiqué sont disponibles sur demande.

KALA BIO (KALA) gab eine Insider-Transaktion durch einen Direktor bekannt. Am 23.10.2025 verkaufte die meldende Person 154.894 Aktien Stammaktien zu einem gewichteten durchschnittlichen Preis von $0.81, wobei einzelne Trades zwischen $0.78 und $0.85 ausgeführt wurden. Nach dem Verkauf besitzt die meldende Person vorteilhaft 103.540 Aktien, berichtet als unvested RSUs, direkt gehalten.

Die Einreichung weist darauf hin, dass der Preis ein gewichteter Durchschnitt ist und dass detaillierte Handelsaufschlüsselungen innerhalb des angegebenen Bereichs auf Anfrage verfügbar sind.

KALA BIO (KALA) كشفت عن عملية داخلية من قبل مدير. في 23/10/2025، باعت الشخص المُبلغ عنه 154,894 سهماً من الأسهم العادية بسعر متوسط مرجح قدره $0.81، مع تنفيذ صفقات فردية بين $0.78 و $0.85. بعد البيع، يملك الشخص المُبلغ عنه بنحو مفاد 103,540 سهماً، مُسجلة كـ RSUs غير vesting ومملوكة بشكل مباشر.

تشير الوثيقة إلى أن السعر هو سعر متوسط مرجح وأن تفصيلات التداول داخل النطاق المحدد متاحة عند الطلب.

KALA BIO (KALA) 披露了一位董事的内部人交易。于 2025/10/23,报告人以加权平均价格 $0.81 出售了 154,894 股普通股,单笔交易价格在 $0.78$0.85 之间。出售后,报告人实际持有 103,540 股,被列为尚未归属的 RSU,直接持有。

申报文件指出价格为加权平均价,且在所述区间内的详细交易分解可按请求提供。

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Iwicki Mark T

(Last) (First) (Middle)
C/O KALA BIO, INC.
1167 MASSACHUSETTS AVENUE

(Street)
ARLINGTON MA 02476

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
KALA BIO, Inc. [ KALA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/23/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/23/2025 S 154,894 D $0.81(1) 103,540(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.78 to $0.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
2. Includes 103,540 unvested RSUs.
/s/ Mary Reumuth, Attorney-in-Fact 10/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did KALA (KALA) report?

A director sold 154,894 shares of common stock on 10/23/2025.

What was the sale price for KALA shares in the Form 4?

The sale used a $0.81 weighted average price, with trades from $0.78 to $0.85.

How many KALA shares does the insider own after the transaction?

The reporting person beneficially owns 103,540 shares, noted as unvested RSUs.

What is the insider’s relationship to KALA BIO?

The reporting person is a Director of KALA BIO.

What is the ownership form of the remaining KALA securities?

The remaining securities are held directly (D).

Does the filing provide detailed trade breakdowns?

Yes. It states detailed numbers per price within $0.78–$0.85 are available upon request.
Kala Pharmaceuticals Inc

NASDAQ:KALA

KALA Rankings

KALA Latest News

KALA Latest SEC Filings

KALA Stock Data

5.31M
6.06M
1.75%
51.86%
5.98%
Biotechnology
Pharmaceutical Preparations
Link
United States
ARLINGTON